UNSPSC 51141597: Tiagabine hydrochloride

This classification denotes an anticonvulsant agent with the molecular formula C20H25NO2S2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DQH6T6D8OY, chemically known as 3-piperidinecarboxylic acid, 1-(4,4-bis(3-methyl-2-thienyl)-3-buten-yl)-, hydrochloride, (r)- but more generally known as tiagabine hydrochloride, which bears US NIH Compound Identifier 91274. European Medicines Agency schedules Tiagabine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15566MIG.

UNSPSC 51141597 Tiagabine hydrochloride is a Commodity code representing a single pharmaceutical product—an anticonvulsant medication. The recent solicitations indexed under this code, however, show a mismatch with the nominal product: the opportunities address naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical distribution agreements rather than tiagabine specifically. This mismatch suggests the code may be used as a placeholder or aggregator for broader pharmaceutical purchasing activity within state and local procurement systems. When solicitations do reference this code, state and local governments are seeking to procure finished pharmaceutical products—tablets, injectable formulations, or other dosage forms—through competitive bidding or cooperative purchasing vehicles, with delivery to health department facilities, community health centers, or authorized wholesaler networks. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP).

Geographic activity appears concentrated in the South and Midwest. Seminole County, Florida issued an IFB on June 30, 2026 (due July 26, 2023 per the posted date discrepancy in the source) for naloxone and drug deactivation systems with quarterly deliveries to a community health building. The Texas Health and Human Services Commission posted an RFI on April 3, 2026 exploring direct-to-manufacturer prescription fulfillment models, signaling potential future formal solicitations. MMCAP, administered by the Minnesota Department of Administration and serving participating states including Oregon, issued an RFP posted January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), with contract terms of two years and optional extensions. The MMCAP opportunity emphasizes FDA compliance, cGMP certification, Drug Supply Chain Security Act adherence, and pricing models weighted 75 percent on price competitiveness. The code's low signal and product misalignment suggest limited recent activity specifically targeting tiagabine hydrochloride procurement at the state and local level.